This inventor holds 1 USPTO granted patent. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Stephen Abbott
Introduction
Stephen Abbott is a notable inventor based in Lexington, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting neurodegenerative diseases. His work focuses on innovative solutions that address critical health challenges.
Latest Patents
Stephen Abbott holds a patent for "Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof." This patent relates to double-stranded ribonucleic acid interference (dsRNAi) agents and compositions that target the microtubule-associated protein tau (MAPT) gene. The invention includes methods for inhibiting the expression of the MAPT gene and treating subjects with MAPT-associated diseases or disorders, such as Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy. He has 1 patent to his name.
Career Highlights
Stephen Abbott is currently employed at Alnylam Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work at Alnylam Pharmaceuticals focuses on innovative therapies that leverage RNA interference technology to treat various diseases.
Collaborations
Stephen collaborates with Jonathan Edward Farley, contributing to the advancement of their shared goals in the field of biotechnology.
Conclusion
Stephen Abbott's innovative work in developing RNA interference agents showcases his commitment to addressing significant health issues. His contributions are paving the way for new therapeutic approaches to neurodegenerative diseases.